Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;25(4):322-328.
doi: 10.1097/MOT.0000000000000776.

Alloimmunity in pancreas transplantation

Fahad Aziz  1 , Didier Mandelbrot  1 , Sandesh Parajuli  1 , Talal Al-Qaoud  2 , Robert Redfield  2 , Dixon Kaufman  2 , Jon S Odorico  2
Affiliations
Review

Alloimmunity in pancreas transplantation

Fahad Aziz et al. Curr Opin Organ Transplant. 2020 Aug.

Abstract

Purpose of review: Despite significant improvement in pancreas allograft survival, rejection continues to be a major clinical problem. This review will focus on emerging literature related to the impact of pretransplant and de-novo DSA (dnDSA) in pancreas transplant recipients, and the diagnosis and treatment of T-cell-medicated rejection (TCMR) and antibody-mediated rejection (ABMR) in this complex group of patients.

Recent findings: Recent data suggest that pretransplant DSA and the emergence of dnDSA in pancreas transplant recipients are both associated with increased risk of ABMR. The pancreas allograft biopsy is essential for the specific diagnosis of TCMR and/or ABMR, distinguish rejection from other causes of graft dysfunction, and to guide-targeted therapy. This distinction is important especially in the setting of solitary pancreas transplants but also in simultaneous pancreas-kidney transplants where solid evidence has now emerged demonstrating discordant biopsy findings. Treatment of rejection in a functioning pancreas can prolong allograft survival.

Summary: The accurate and timely diagnosis of active alloimmune destruction in pancreas transplant recipients is paramount to preserving graft function in the long term. This review will discuss new, rapidly evolving information that is valuable for the physician caring for these patients to achieve optimal immunological outcomes.

PubMed Disclaimer

References

    1. van Dellen D, Worthington J, Mitu-Pretorian OM, et al. Mortality in diabetes: pancreas transplantation is associated with significant survival benefit. Nephrol Dial Transplant 2013; 28:1315–1322.
    1. Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg 2015; 150:252–259.
    1. Posegger KR, Linhares MM, Mucci S, et al. The quality of life in type I diabetic patients with end-stage kidney disease before and after simultaneous pancreas-kidney transplantation: a single-center prospective study. Transpl Int 2019; 33:330–339.
    1. Nathan DM, Fogel H, Norman D, et al. Long-term metabolic and quality of life results with pancreatic/renal transplantation in insulin-dependent diabetes mellitus. Transplantation 1991; 52:85–91.
    1. Alhamad F, Stratta RJ. Brennan DC, Nathan DM. UpToDate, Pancreas-kidney transplantation in diabetes mellitus: benefits and complications. Waltham, MA: 2019.